Proinvasive properties of ovarian cancer ascites-derived membrane vesicles

Cancer Research

Volumn 64, Issue 19, 2004, Pages 7045-7049

  Graves, Laura E ^a   Ariztia, Edgardo V ^b   Navari, Jason R ^a   Matzel, Heather J ^a   Stack, M Sharon ^a   Fishman, David A ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GELATINASE B; MATRIGEL; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; SCLEROPROTEIN; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; ASCITES; CANCER CELL; CANCER INVASION; CANCER STAGING; CELL INVASION; CELL ISOLATION; COLORIMETRY; CONTROLLED STUDY; EPITHELIUM; FEMALE; FRACTIONATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MEMBRANE STRUCTURE; MEMBRANE VESICLE; OVARY CANCER; OVARY CELL CULTURE; OVARY METASTASIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; SUPERNATANT; ULTRACENTRIFUGE; WESTERN BLOTTING; ZYMOGRAPHY;

EID: 4944223380     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1800     Document Type: Article

References (29)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA-Cancer J Clin 2001;51:15-36.
2. Young TN, Rodriguez GC, Rinehart AR, et al. Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. Gynecol Oncol 1996;62:89-99.
3. Fishman DA, Bafetti LM, Banionis S, et al. Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian cancer cells. Cancer (Phila) 1997;80:1457-63.
4. Fishman DA, Liu Y, Ellerbroek SM, Stack MS. Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res 2001;61:3194-9.
5. Ellerbroek SM, Fishman DA, Kearns AS, Bafetti LM, Stack MS. Ovarian carcinoma regulation of matrix metalloproteinase-2 and membrane-type I matrix metalloproteinase through beta 1 integrin. Cancer Res 1999;59:1635-41.
6. Moser TL, Young TN, Rodriguez GC, et al. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Int J Cancer 1994;56:552-9.
7. Kobayashi H, Ohi H, Sugimura M, et al. Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res 1992;52:3610-4.
8. Puls LE, Duniho T, Hunter JE, et al. The prognostic implication of ascites in advanced-stage ovarian cancer. Gynecol Oncol 1996;61:109-12.
9. Dembo AJ, Davy M, Stenwig AE, et al. Prognostic factors in patients with stage I epithelial ovarian carcinoma. Obstet Gynecol 1990;75:263-73.
10. Dolo V, D'Ascenzo S, Violini S, et al. Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro. Clin Exp Metastasis 1999;17:131-40.
11. Ginestra A, Miceli D, Dolo V, Romano FM, Vitorelli ML. Membrane vesicles in ovarian cancer fluids: a new potential marker. Anticancer Res 1999;19:3429-45.
12. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
13. Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 1980;102:196-202.
14. Moser TL, Enghild JJ, Pizzo SV, Stack MS. Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA-dependent adhesion of U937 cells. Biochem J 1995;307:867-73.
15. Ellerbroek SM, Wu YI, Overall CM, Stack MS. Functional interplay between type I collagen and cell surface matrix metalloproteinase activity. J Biol Chem 2001;276: 24833-42.
16. Ellerbroek SM, Hudson LG, Stack MS. Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion. Int J Cancer 1998;78:331-7.
17. Taverna S, Ghersi G, Ginestra A, et al. Shedding of membrane vesicles mediates fibroblast growth factor-2 release from cells. J Biol Chem 2003;278:51911-9.
18. Dolo V, Adobati E, Canevari S, Picone MA, Vittotelli ML. Membrane vesicles shed into the extracellular medium by human breast carcinoma cells carry tumor-associated antigens. Clin Exp Metastasis 1995;13:277-86.
19. Angelucci A, D'Ascenzo S, Festuccia C, et al. Vesicle-associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines. Clin Exp Metastasis 2000;18:163-70.
20. Ginestra A, Monea S, Seghezzi G, et al. Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J Biol Chem 1997;272:17216-22.
21. Dolo V, Ginestra A, Cassara D, et al. Selective localization of matrix metalloproteinase 9, beta 1 integrins, and human lymphocyte antigen class 1 molecules on membrane vesicles shed by 8701-BC breast carcinoma cells. Cancer Res 1998;58:4468-74.
22. 3H- thymtdine incorporation, are neutralized by anti TGF-beta antibodies. J Submicrosc Cytol Pathol 1995;27:535-41.
23. Taylor DD, Gerçel-Taylor Ç, Lyons KS, Stanson J, Whiteside TL. T-cell apoptosis and suppression of T-cell receptor/CD63-ζ by Fas ligand-containing membrane vesicles shed from ovarian tumors. Clin Cancer Res 2003;9:5113-9.
24. Yousef GM, Polymeris ME, Yacoub GM, et al. Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res 2003;63:2223-7.
25. Yousef GM, Polymeris ME, Grass L, et al. Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. Cancer Res 2003;63:3958-65.
26. Diamandis EP, Scorilas A, Fracchioli S, et al. Human kallirein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian cancer. J Clin Oncol 2003;21:1035-43.
27. Magklara A, Mellati AA, Wasney GA, et al. Characterization of the enzymatic activity of human kallikrein 6: autoactivation, substrate specificity, and regulation by inhibitors. Biochem Biophys Res Commun 2003;307:948-55.
28. Luo LY, Katsaros D, Scorilas A, et al. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res 2003;63:807-11.
29. Borgono CA, Grass L, Soosaipillai A, et al. Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. Cancer Res 2003;63:9032-41.